The list of things GLP-1 medications might do keeps getting longer. The latest comes from cancer research: a large study, summarized by the American Society of Clinical Oncology (ASCO), found that people taking GLP-1s were less likely to see certain cancers spread than people on an older class of diabetes drugs.

Here's what the researchers did. They pulled the health records of more than 12,000 people worldwide, all of whom had 1 of 7 cancers tied to diabetes and obesity — breast, prostate, lung, colorectal, liver, kidney, or pancreatic — caught at stage I, II, or III, before it had spread. Half were taking a GLP-1; half were taking a gliptin (a DPP-4 inhibitor). Then they tracked how often the cancer progressed to stage IV, meaning it had metastasized.

In 4 of the 7 cancers (lung, breast, colorectal, and liver), fewer people on GLP-1s progressed to stage IV. Depending on the cancer type, the GLP-1 group saw the risk of spread drop by roughly 40% to 50% compared to the gliptin group.

Why might a weight-loss and diabetes drug affect cancer at all? The leading theory is that GLP-1s do more than lower blood sugar. As one of the commenting experts put it, these drugs "have never been just glucose-lowering drugs" — their anti-inflammatory and immune-modulatory effects may make the body a less hospitable place for cancer to grow (KFF).

A few caveats, because they matter here include that this was observational research built on existing records, not a controlled trial. It shows an association, not proof that GLP-1s cause the slowdown. The study authors are careful about this, calling it "early evidence that future studies are worth pursuing", and the experts agree the findings are strong enough to justify a proper randomized trial, not to change treatment today. No one should start, stop, or switch a medication based on this study (KFF).

This is one more data point in a story we've been tracking all year: GLP-1s are turning out to be far more than weight-loss drugs, and the research, the products, and the public conversation around them are moving fast. Roughly 1 in 5 people with cancer also has diabetes, and these medications are already in tens of millions of hands. The people walking into your club are part of that wave — and they're paying attention to every headline.

Staying ahead of that conversation is exactly why we publish the Inspire360 GLP-1 Club Intelligence Report. Our Q1 2026 edition broke down how clubs and solution providers are adapting to the GLP-1 era, and the Q2 report is coming soon with the latest developments. Read Q1 here, and watch for Q2.

‍